263 related articles for article (PubMed ID: 21378270)
1. The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia.
Herman SE; Lapalombella R; Gordon AL; Ramanunni A; Blum KA; Jones J; Zhang X; Lannutti BJ; Puri KD; Muthusamy N; Byrd JC; Johnson AJ
Blood; 2011 Apr; 117(16):4323-7. PubMed ID: 21378270
[TBL] [Abstract][Full Text] [Related]
2. Molecular pathways: targeting phosphoinositide 3-kinase p110-delta in chronic lymphocytic leukemia.
Herman SE; Johnson AJ
Clin Cancer Res; 2012 Aug; 18(15):4013-8. PubMed ID: 22711705
[TBL] [Abstract][Full Text] [Related]
3. Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway.
Lapalombella R; Andritsos L; Liu Q; May SE; Browning R; Pham LV; Blum KA; Blum W; Ramanunni A; Raymond CA; Smith LL; Lehman A; Mo X; Jarjoura D; Chen CS; Ford R; Rader C; Muthusamy N; Johnson AJ; Byrd JC
Blood; 2010 Apr; 115(13):2619-29. PubMed ID: 19965642
[TBL] [Abstract][Full Text] [Related]
4. Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals.
Herman SE; Gordon AL; Wagner AJ; Heerema NA; Zhao W; Flynn JM; Jones J; Andritsos L; Puri KD; Lannutti BJ; Giese NA; Zhang X; Wei L; Byrd JC; Johnson AJ
Blood; 2010 Sep; 116(12):2078-88. PubMed ID: 20522708
[TBL] [Abstract][Full Text] [Related]
5. Idelalisib.
Zirlik K; Veelken H
Recent Results Cancer Res; 2018; 212():243-264. PubMed ID: 30069634
[TBL] [Abstract][Full Text] [Related]
6. IGF1R as druggable target mediating PI3K-δ inhibitor resistance in a murine model of chronic lymphocytic leukemia.
Scheffold A; Jebaraj BMC; Tausch E; Bloehdorn J; Ghia P; Yahiaoui A; Dolnik A; Blätte TJ; Bullinger L; Dheenadayalan RP; Li L; Schneider C; Chen SS; Chiorazzi N; Dietrich S; Seiffert M; Tannheimer S; Döhner H; Mertens D; Stilgenbauer S
Blood; 2019 Aug; 134(6):534-547. PubMed ID: 31010847
[TBL] [Abstract][Full Text] [Related]
7. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia.
Hoellenriegel J; Meadows SA; Sivina M; Wierda WG; Kantarjian H; Keating MJ; Giese N; O'Brien S; Yu A; Miller LL; Lannutti BJ; Burger JA
Blood; 2011 Sep; 118(13):3603-12. PubMed ID: 21803855
[TBL] [Abstract][Full Text] [Related]
8. Lenalidomide Induces Interleukin-21 Production by T Cells and Enhances IL21-Mediated Cytotoxicity in Chronic Lymphocytic Leukemia B Cells.
Browning RL; Byrd WH; Gupta N; Jones J; Mo X; Hertlein E; Yu L; Muthusamy N; Byrd JC
Cancer Immunol Res; 2016 Aug; 4(8):698-707. PubMed ID: 27287425
[TBL] [Abstract][Full Text] [Related]
9. How does lenalidomide target the chronic lymphocytic leukemia microenvironment?
Kater AP; Tonino SH; Egle A; Ramsay AG
Blood; 2014 Oct; 124(14):2184-9. PubMed ID: 25161268
[TBL] [Abstract][Full Text] [Related]
10. Lenalidomide in the treatment of chronic lymphocytic leukemia.
Itchaki G; Brown JR
Expert Opin Investig Drugs; 2017 May; 26(5):633-650. PubMed ID: 28388253
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of phosphatidylinositol-3 kinase inhibitors with diverse isoform selectivity profiles for inhibiting the survival of chronic lymphocytic leukemia cells.
Göckeritz E; Kerwien S; Baumann M; Wigger M; Vondey V; Neumann L; Landwehr T; Wendtner CM; Klein C; Liu N; Hallek M; Frenzel LP; Krause G
Int J Cancer; 2015 Nov; 137(9):2234-42. PubMed ID: 25912635
[TBL] [Abstract][Full Text] [Related]
12. Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer.
Ramsay AG; Clear AJ; Fatah R; Gribben JG
Blood; 2012 Aug; 120(7):1412-21. PubMed ID: 22547582
[TBL] [Abstract][Full Text] [Related]
13. Activation of the MAPK pathway mediates resistance to PI3K inhibitors in chronic lymphocytic leukemia.
Murali I; Kasar S; Naeem A; Tyekucheva S; Khalsa JK; Thrash EM; Itchaki G; Livitz D; Leshchiner I; Dong S; Fernandes SM; Getz G; Johnson A; Brown JR
Blood; 2021 Jul; 138(1):44-56. PubMed ID: 33684943
[TBL] [Abstract][Full Text] [Related]
14. Lenalidomide alone and in combination for chronic lymphocytic leukemia.
Chen CI
Curr Hematol Malig Rep; 2013 Mar; 8(1):7-13. PubMed ID: 23254517
[TBL] [Abstract][Full Text] [Related]
15. Lenalidomide induces immunomodulation in chronic lymphocytic leukemia and enhances antitumor immune responses mediated by NK and CD4 T cells.
Acebes-Huerta A; Huergo-Zapico L; Gonzalez-Rodriguez AP; Fernandez-Guizan A; Payer AR; López-Soto A; Gonzalez S
Biomed Res Int; 2014; 2014():265840. PubMed ID: 25313353
[TBL] [Abstract][Full Text] [Related]
16. Role of chemokines and their receptors in chronic lymphocytic leukemia: function in microenvironment and targeted therapy.
Han TT; Fan L; Li JY; Xu W
Cancer Biol Ther; 2014 Jan; 15(1):3-9. PubMed ID: 24149438
[TBL] [Abstract][Full Text] [Related]
17. Single-agent lenalidomide in the treatment of previously untreated chronic lymphocytic leukemia.
Chen CI; Bergsagel PL; Paul H; Xu W; Lau A; Dave N; Kukreti V; Wei E; Leung-Hagesteijn C; Li ZH; Brandwein J; Pantoja M; Johnston J; Gibson S; Hernandez T; Spaner D; Trudel S
J Clin Oncol; 2011 Mar; 29(9):1175-81. PubMed ID: 21189385
[TBL] [Abstract][Full Text] [Related]
18. Thalidomide and lenalidomide as new therapeutics for the treatment of chronic lymphocytic leukemia.
Awan FT; Johnson AJ; Lapalombella R; Hu W; Lucas M; Fischer B; Byrd JC
Leuk Lymphoma; 2010 Jan; 51(1):27-38. PubMed ID: 20055657
[TBL] [Abstract][Full Text] [Related]
19. Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response.
Chanan-Khan AA; Chitta K; Ersing N; Paulus A; Masood A; Sher T; Swaika A; Wallace PK; Mashtare TL; Wilding G; Lee K; Czuczman MS; Borrello I; Bangia N
Br J Haematol; 2011 Nov; 155(4):457-67. PubMed ID: 22010965
[TBL] [Abstract][Full Text] [Related]
20. Immunomodulators in chronic lymphocytic leukemia: where does lenalidomide belong?
Brown JR
Leuk Lymphoma; 2010 Aug; 51(8):1382-5. PubMed ID: 20624030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
